Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation

J Am Acad Dermatol. 1993 Nov;29(5 Pt 1):729-35. doi: 10.1016/0190-9622(93)70238-o.

Abstract

Background: Topical diphenylcyclopropenone (DPCP) and minoxidil have been used in the treatment of alopecia areata with variable results.

Objective: This study was designed to evaluate the efficacy of DPCP alone or in combination with topical 5% minoxidil for the treatment of chronic severe alopecia areata. The effect of therapy on cutaneous T-cell and Langerhans cell subpopulations and intercellular adhesion molecule-1 (ICAM-1) expression was also examined.

Methods: Fifteen patients with chronic (more than 2 years), severe (more than 50% scalp involvement) alopecia areata participated in a 24-week trial. Half of the scalp was treated with DPCP once weekly and with either 5% minoxidil solution or a vehicle solution twice daily in a randomized double-blind design. Skin biopsy specimens from each half of the scalp were obtained before therapy and after 12 and 24 weeks of therapy for histologic and immunophenotypic analysis.

Results: Thirteen patients completed the study. Five of 13 patients (38%) showed marked regrowth of coarse terminal hair after 24 weeks of treatment with DPCP. The addition of topical 5% minoxidil did not produce any significant clinical benefit in this 24-week trial. Immunophenotypic analysis showed no differences between responders and nonresponders at baseline. During treatment, Leu-4, Leu-2, Leu-3, and keratinocyte ICAM-1 expression were significantly reduced in biopsy specimens of responders versus nonresponders.

Conclusion: DPCP treatment showed a 38% success rate in producing cosmetically acceptable regrowth in patients with chronic severe alopecia areata.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Aged
  • Alopecia / drug therapy*
  • Alopecia / immunology*
  • Alopecia / pathology
  • Antibodies, Monoclonal
  • Antigens, CD / biosynthesis
  • Antigens, CD / drug effects
  • CD4 Antigens / biosynthesis
  • CD4 Antigens / drug effects
  • CD8 Antigens / biosynthesis
  • CD8 Antigens / drug effects
  • Cell Adhesion Molecules / biosynthesis
  • Cell Adhesion Molecules / drug effects
  • Chronic Disease
  • Cyclopropanes / therapeutic use*
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunophenotyping
  • Intercellular Adhesion Molecule-1
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Langerhans Cells / drug effects
  • Langerhans Cells / metabolism
  • Male
  • Middle Aged
  • Minoxidil / therapeutic use*
  • Severity of Illness Index
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocyte Subsets / pathology

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • CD4 Antigens
  • CD8 Antigens
  • Cell Adhesion Molecules
  • Cyclopropanes
  • Intercellular Adhesion Molecule-1
  • Minoxidil
  • diphenylcyclopropenone